{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:55:14Z","timestamp":1781650514404,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intrahepatic cholangiocarcinoma (iCCA) is an aggressive primary liver malignancy with rising incidence and poor outcomes. Most patients present with unresectable disease, with mortality frequently driven by intrahepatic tumor burden and liver failure, making local control (LC) a central treatment goal. External beam radiation therapy (EBRT) plays an expanding role in multidisciplinary care, enabled by modern planning, image guidance, and motion management techniques that permit safe dose escalation. Across definitive EBRT series, a consistent dose\u2013response relationship is observed. Higher biologically effective doses (BED) have been associated with improved outcomes, with BED\u2009&gt;\u200980.5\u00a0Gy achieving superior 3-year LC and overall survival (OS) compared with lower-dose regimens. Dose-escalated approaches have reported 2-year LC rates of 80\u201390% and median OS approaching 20\u201330 months in selected patients. Advanced technologies such as proton beam therapy and MR-guided radiotherapy may further improve the therapeutic ratio, with reported grade 3 or higher toxicity rates below 8% and one- to two-year LC rates exceeding 90% in PBT series. Beyond definitive therapy, EBRT contributes to tumor downstaging, enabling surgical resection in approximately 10\u201330% of initially unresectable patients, and may improve survival in selected metastatic or liver-dominant disease. Early-phase data combining EBRT with immune checkpoint inhibition are emerging and warrant prospective validation.<\/jats:p>","DOI":"10.1007\/s12029-026-01463-5","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:49:20Z","timestamp":1776401360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["External Beam Radiation Therapy for Intrahepatic Cholangiocarcinoma"],"prefix":"10.1007","volume":"57","author":[{"given":"Alexandra E.","family":"Hotca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"11","key":"1463_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s10552-025-02038-8","volume":"36","author":"A Khan","year":"2025","unstructured":"Khan A, Tareen A, Ashraf SU, et al. Intrahepatic cholangiocarcinoma mortality in the USA, 1999\u20132020: a 21-year population-based analysis. Cancer Causes Control. 2025;36(11):1511\u201323. https:\/\/doi.org\/10.1007\/s10552-025-02038-8.","journal-title":"Cancer Causes Control."},{"issue":"2","key":"1463_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","volume":"51","author":"M Qurashi","year":"2025","unstructured":"Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2025;51(2):107064. https:\/\/doi.org\/10.1016\/j.ejso.2023.107064.","journal-title":"Eur J Surg Oncol"},{"issue":"10272","key":"1463_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Dy O, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7.","journal-title":"Lancet"},{"issue":"17","key":"1463_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174217","volume":"15","author":"H Bourien","year":"2023","unstructured":"Bourien H, Pircher CC, Guiu B, et al. Locoregional treatment in intrahepatic cholangiocarcinoma: which treatment for which patient? Cancers. 2023;15(17):4217. https:\/\/doi.org\/10.3390\/cancers15174217.","journal-title":"Cancers"},{"key":"1463_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102258","volume":"99","author":"J Edeline","year":"2021","unstructured":"Edeline J, Lamarca A, McNamara MG, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev. 2021;99:102258. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102258.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"1463_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365. https:\/\/doi.org\/10.1097\/HEP.0000000000000466.","journal-title":"Hepatology"},{"issue":"2","key":"1463_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.14157","volume":"25","author":"NC Busse","year":"2024","unstructured":"Busse NC, Al-Ghazi MSAL MSAL, Abi\u2010Jaoudeh N, et al. AAPM medical physics practice guideline 14.a: yttrium\u201090 microsphere radioembolization. J Appl Clin Med Phys. 2024;25(2):e14157. https:\/\/doi.org\/10.1002\/acm2.14157.","journal-title":"J Appl Clin Med Phys"},{"key":"1463_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ctro.2019.07.007","volume":"19","author":"NT Sebastian","year":"2019","unstructured":"Sebastian NT, Tan Y, Miller ED, Williams TM, Alexandra Diaz D. Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma. Clin Transl Radiat Oncol. 2019;19:66\u201371. https:\/\/doi.org\/10.1016\/j.ctro.2019.07.007.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"1463_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","volume":"44","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Solaini L, Vara G, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma\u2014a systemic review and meta-analysis. Cardiovasc Intervent Radiol. 2021;44(5):728\u201338. https:\/\/doi.org\/10.1007\/s00270-021-02800-w.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"1463_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00270-023-03657-x","volume":"47","author":"P Reimer","year":"2024","unstructured":"Reimer P, Vilgrain V, Arnold D, et al. Factors impacting survival after transarterial radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: a combined analysis of the prospective CIRT studies. Cardiovasc Intervent Radiol. 2024;47(3):310\u201324. https:\/\/doi.org\/10.1007\/s00270-023-03657-x.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"1463_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","volume":"26","author":"RV Tse","year":"2008","unstructured":"Tse RV, Hawkins M, Lockwood G, et al. Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2008;26(4):657\u201364. https:\/\/doi.org\/10.1200\/JCO.2007.14.3529.","journal-title":"J Clin Oncol."},{"key":"1463_CR12","doi-asserted-by":"crossref","unstructured":"Lee IJ, Bang JI, Choi SH, Im JH. Optimizing radiotherapy in unresectable or metastatic intrahepatic cholangiocarcinoma: systematic review and meta-analysis of the literature. Radiat Oncol. Published online December 13, 2025. doi:10.1186\/s13014-025-02777-7","DOI":"10.1186\/s13014-025-02777-7"},{"issue":"2","key":"1463_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659\u2013702. https:\/\/doi.org\/10.1002\/hep.32771.","journal-title":"Hepatology"},{"issue":"4","key":"1463_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1245\/s10434-019-08142-9","volume":"27","author":"AC Smart","year":"2020","unstructured":"Smart AC, Goyal L, Horick N, et al. Hypofractionated radiation therapy for unresectable\/locally recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020;27(4):1122\u20139. https:\/\/doi.org\/10.1245\/s10434-019-08142-9.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1463_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","volume":"34","author":"R Tao","year":"2016","unstructured":"Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol. 2016;34(3):219\u201326. https:\/\/doi.org\/10.1200\/JCO.2015.61.3778.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1463_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00066-018-1367-2","volume":"195","author":"J Lee","year":"2019","unstructured":"Lee J, Yoon WS, Koom WS, Rim CH. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol. 2019;195(2):93\u2013102. https:\/\/doi.org\/10.1007\/s00066-018-1367-2.","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"1463_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0360-3016(02)02845-6","volume":"53","author":"CH Crane","year":"2002","unstructured":"Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002;53(4):969\u201374. https:\/\/doi.org\/10.1016\/S0360-3016(02)02845-6.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1463_CR18","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19909","volume":"13","author":"P Liu","year":"2025","unstructured":"Liu P, Ye H, Song L, Li H, Fu M, Dong Z. Outcomes of stereotactic body radiotherapy for unresectable cholangiocarcinoma: a meta-analysis and systematic review. PeerJ. 2025;13:e19909. https:\/\/doi.org\/10.7717\/peerj.19909.","journal-title":"PeerJ"},{"issue":"16_suppl","key":"1463_CR19","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/JCO.2024.42.16_suppl.4006","volume":"42","author":"MA Hawkins","year":"2024","unstructured":"Hawkins MA, Valle JW, Wasan HS, et al. Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): results from a randomized phase II trial. J Clin Oncol. 2024;42(16_suppl):4006\u20134006. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4006.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1463_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","volume":"12","author":"S Apisarnthanarax","year":"2022","unstructured":"Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12(1):28\u201351. https:\/\/doi.org\/10.1016\/j.prro.2021.09.004.","journal-title":"Pract Radiat Oncol"},{"key":"1463_CR21","doi-asserted-by":"crossref","unstructured":"Yamazaki H, Shibuya K, Kimoto T, et al. Proton Beam Therapy for Intrahepatic and Perihilar Cholangiocarcinoma: A Multicenter Prospective Registry Study: Potential Candidates for High-Dose Proton Beam Therapy. Int J Radiat Oncol. Published online December 2025:S0360301625065356. doi:10.1016\/j.ijrobp.2025.11.057","DOI":"10.1016\/j.ijrobp.2025.11.057"},{"issue":"5","key":"1463_CR22","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","volume":"34","author":"TS Hong","year":"2016","unstructured":"Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34(5):460\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.2710.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1463_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01703-3","volume":"15","author":"JS Parzen","year":"2020","unstructured":"Parzen JS, Hartsell W, Chang J, et al. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the proton collaborative group. Radiat Oncol. 2020;15(1):255. https:\/\/doi.org\/10.1186\/s13014-020-01703-3.","journal-title":"Radiat Oncol"},{"issue":"3","key":"1463_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","volume":"126","author":"L Henke","year":"2018","unstructured":"Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126(3):519\u201326. https:\/\/doi.org\/10.1016\/j.radonc.2017.11.032.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1463_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.adro.2018.08.005","volume":"4","author":"SA Rosenberg","year":"2019","unstructured":"Rosenberg SA, Henke LE, Shaverdian N, et al. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Adv Radiat Oncol. 2019;4(1):142\u20139. https:\/\/doi.org\/10.1016\/j.adro.2018.08.005.","journal-title":"Adv Radiat Oncol"},{"issue":"8","key":"1463_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s00066-017-1128-7","volume":"193","author":"Y Cho","year":"2017","unstructured":"Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlenther Onkol. 2017;193(8):620\u20139. https:\/\/doi.org\/10.1007\/s00066-017-1128-7.","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"1463_CR27","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1007\/s00268-018-4558-1","volume":"42","author":"T Sumiyoshi","year":"2018","unstructured":"Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg. 2018;42(9):2910\u20138. https:\/\/doi.org\/10.1007\/s00268-018-4558-1.","journal-title":"World J Surg"},{"issue":"3","key":"1463_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/lv.2000.6143","volume":"6","author":"I De Vreede","year":"2000","unstructured":"De Vreede I, Steers JL, Burch PA, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000;6(3):309\u201316. https:\/\/doi.org\/10.1053\/lv.2000.6143.","journal-title":"Liver Transpl"},{"issue":"2","key":"1463_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jso.24833","volume":"117","author":"BPT Loveday","year":"2018","unstructured":"Loveday BPT, Knox JJ, Dawson LA, et al. Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada. J Surg Oncol. 2018;117(2):213\u20139. https:\/\/doi.org\/10.1002\/jso.24833.","journal-title":"J Surg Oncol"},{"issue":"3","key":"1463_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/lt.26285","volume":"28","author":"T Ito","year":"2022","unstructured":"Ito T, Butler JR, Noguchi D, et al. A 3-Decade, Single-Center Experience of Liver Transplantation for Cholangiocarcinoma: Impact of Era, Tumor Size, Location, and Neoadjuvant Therapy. Liver Transpl. 2022;28(3):386\u201396. https:\/\/doi.org\/10.1002\/lt.26285.","journal-title":"Liver Transpl."},{"issue":"2","key":"1463_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrad025","volume":"7","author":"FJH Hoogwater","year":"2023","unstructured":"Hoogwater FJH, Kuipers H, De Meijer VE, et al. Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: multicentre, retrospective cohort study. BJS Open. 2023;7(2):zrad025. https:\/\/doi.org\/10.1093\/bjsopen\/zrad025.","journal-title":"BJS Open"},{"key":"1463_CR32","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines with Evidence Blocks: Biliary Tract Cancers. Accessed January 2, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc_blocks.pdf"},{"issue":"4","key":"1463_CR33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/hep.28744","volume":"64","author":"G Sapisochin","year":"2016","unstructured":"Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178\u201388. https:\/\/doi.org\/10.1002\/hep.28744.","journal-title":"Hepatology"},{"issue":"6","key":"1463_CR34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/lt.25737","volume":"26","author":"E De Martin","year":"2020","unstructured":"De Martin E, Rayar M, Golse N, et al. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl. 2020;26(6):785\u201398. https:\/\/doi.org\/10.1002\/lt.25737.","journal-title":"Liver Transpl"},{"issue":"5","key":"1463_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","volume":"3","author":"KE Lunsford","year":"2018","unstructured":"Lunsford KE, Javle M, Heyne K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3(5):337\u201348. https:\/\/doi.org\/10.1016\/S2468-1253(18)30045-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1463_CR36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ajt.16906","volume":"22","author":"RR McMillan","year":"2022","unstructured":"McMillan RR, Javle M, Kodali S, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. 2022;22(3):823\u201332. https:\/\/doi.org\/10.1111\/ajt.16906.","journal-title":"Am J Transplant"},{"issue":"3","key":"1463_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.hpb.2023.12.004","volume":"26","author":"TC Wu","year":"2024","unstructured":"Wu TC, Deng J, Chu FI, et al. Single center experience using stereotactic body radiation therapy (SBRT) on orthotopic liver transplant protocol for unresectable cholangiocarcinoma. HPB. 2024;26(3):444\u201350. https:\/\/doi.org\/10.1016\/j.hpb.2023.12.004.","journal-title":"HPB"},{"issue":"12","key":"1463_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2025.102211","volume":"29","author":"R Anteby","year":"2025","unstructured":"Anteby R, Vierra BM, Shah SA. Liver transplant for intrahepatic cholangiocarcinoma: current evidence and clinical practice recommendations. J Gastrointest Surg. 2025;29(12):102211. https:\/\/doi.org\/10.1016\/j.gassur.2025.102211.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"1463_CR39","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijrobp.2008.03.018","volume":"72","author":"ET Shinohara","year":"2008","unstructured":"Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2008;72(5):1495\u2013501. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.03.018.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1463_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.radonc.2018.05.011","volume":"128","author":"YK Lin","year":"2018","unstructured":"Lin YK, Hsieh MC, Wang WW, et al. Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy. Radiother Oncol. 2018;128(3):575\u201383. https:\/\/doi.org\/10.1016\/j.radonc.2018.05.011.","journal-title":"Radiother Oncol"},{"issue":"10","key":"1463_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.hpb.2016.07.008","volume":"18","author":"LL Dover","year":"2016","unstructured":"Dover LL, Oster RA, McDonald AM, DuBay DA, Wang TN, Jacob R. Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma. HPB. 2016;18(10):843\u201350. https:\/\/doi.org\/10.1016\/j.hpb.2016.07.008.","journal-title":"HPB"},{"issue":"16","key":"1463_CR42","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u201340. https:\/\/doi.org\/10.1200\/JCO.2011.40.5381.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1463_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229292","volume":"15","author":"Q Ke","year":"2020","unstructured":"Ke Q, Lin N, Deng M, Wang L, Zeng Y, Liu J. The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: a systematic review and meta-analysis. Alpini GD, ed. PLoS One. 2020;15(2):e0229292. https:\/\/doi.org\/10.1371\/journal.pone.0229292.","journal-title":"PLoS One"},{"issue":"3","key":"1463_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030494","volume":"17","author":"YD Seo","year":"2025","unstructured":"Seo YD, Acidi B, Newton A, et al. Defining the role of adjuvant radiotherapy for biliary tract cancers: a site-specific propensity-matched analysis. Cancers. 2025;17(3):494. https:\/\/doi.org\/10.3390\/cancers17030494.","journal-title":"Cancers"},{"issue":"16_suppl","key":"1463_CR45","doi-asserted-by":"publisher","first-page":"e16277","DOI":"10.1200\/JCO.2024.42.16_suppl.e16277","volume":"42","author":"A Mohsin","year":"2024","unstructured":"Mohsin A, Ahmad S, Khan HD, et al. Survival outcomes in patients with non-metastatic intrahepatic cholangiocarcinoma in United States: A nationwide analysis. J Clin Oncol. 2024;42(16_suppl):e16277\u2013e16277. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e16277.","journal-title":"J Clin Oncol."},{"key":"1463_CR46","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers. Version 1.2025. National Comprehensive Cancer Network; 2025. Accessed January 2, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf"},{"issue":"12","key":"1463_CR47","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015\u201327. https:\/\/doi.org\/10.1200\/JCO.18.02178.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1463_CR48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000530134","volume":"12","author":"B De","year":"2023","unstructured":"De B, Upadhyay R, Liao K, et al. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer. 2023;12(3):198\u2013208. https:\/\/doi.org\/10.1159\/000530134.","journal-title":"Liver Cancer."},{"issue":"5","key":"1463_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2025.102584","volume":"15","author":"D Sharma","year":"2025","unstructured":"Sharma D, Meena BL, Himthani N, et al. Stereotactic Body Radiation Therapy in Advanced Intrahepatic Cholangiocarcinoma: Real-world Outcomes from an Indian Cohort. J Clin Exp Hepatol. 2025;15(5): 102584. https:\/\/doi.org\/10.1016\/j.jceh.2025.102584.","journal-title":"J Clin Exp Hepatol."},{"issue":"9","key":"1463_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11154","volume":"2","author":"NT Sebastian","year":"2019","unstructured":"Sebastian NT, Tan Y, Miller ED, et al. Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma. JAMA Netw Open. 2019;2(9): e1911154. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11154.","journal-title":"JAMA Netw Open."},{"issue":"1","key":"1463_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-492","volume":"10","author":"YX Chen","year":"2010","unstructured":"Chen YX, Zeng ZC, Tang ZY, et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer. 2010;10(1):492. https:\/\/doi.org\/10.1186\/1471-2407-10-492.","journal-title":"BMC Cancer"},{"issue":"2","key":"1463_CR52","first-page":"113","volume":"12","author":"ZC Zeng","year":"2006","unstructured":"Zeng ZC, Tang ZY, Fan J, et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients. Cancer J Sudbury Mass. 2006;12(2):113\u201322.","journal-title":"Cancer J Sudbury Mass."},{"issue":"10","key":"1463_CR53","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S1470-2045(24)00438-8","volume":"25","author":"LA Dawson","year":"2024","unstructured":"Dawson LA, Ringash J, Fairchild A, et al. Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2024;25(10):1337\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(24)00438-8.","journal-title":"Lancet Oncol."},{"issue":"1","key":"1463_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010050","volume":"15","author":"J Jiang","year":"2022","unstructured":"Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A. Stereotactic body radiation therapy (SBRT) plus immune checkpoint inhibitors (ICI) in hepatocellular carcinoma and cholangiocarcinoma. Cancers. 2022;15(1):50. https:\/\/doi.org\/10.3390\/cancers15010050.","journal-title":"Cancers"},{"key":"1463_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4304817","volume":"2019","author":"M Kreidieh","year":"2019","unstructured":"Kreidieh M, Zeidan YH, Shamseddine A. The combination of stereotactic body radiation therapy and immunotherapy in primary liver tumors. J Oncol. 2019;2019:1\u201313. https:\/\/doi.org\/10.1155\/2019\/4304817.","journal-title":"J Oncol"},{"issue":"1","key":"1463_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03381-4","volume":"22","author":"M Zhu","year":"2024","unstructured":"Zhu M, Jin M, Zhao X, et al. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Med. 2024;22(1):165. https:\/\/doi.org\/10.1186\/s12916-024-03381-4.","journal-title":"BMC Med"},{"issue":"1","key":"1463_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0692-z","volume":"7","author":"X Liu","year":"2019","unstructured":"Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer. 2019;7(1):204. https:\/\/doi.org\/10.1186\/s40425-019-0692-z.","journal-title":"J Immunother Cancer"},{"key":"1463_CR58","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fmed.2020.00368","volume":"7","author":"ZL Liu","year":"2020","unstructured":"Liu ZL, Liu X, Peng H, et al. Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report. Front Med. 2020;7:368. https:\/\/doi.org\/10.3389\/fmed.2020.00368.","journal-title":"Front Med."},{"issue":"3","key":"1463_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/15384047.2020.1834792","volume":"22","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Chen Y, Du S, et al. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther. 2021;22(3):175\u201383. https:\/\/doi.org\/10.1080\/15384047.2020.1834792.","journal-title":"Cancer Biol Ther."},{"issue":"1","key":"1463_CR60","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1186\/s12885-022-10373-1","volume":"22","author":"C Elias","year":"2022","unstructured":"Elias C, Zeidan YH, Bouferraa Y, et al. A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). BMC Cancer. 2022;22(1):1296. https:\/\/doi.org\/10.1186\/s12885-022-10373-1.","journal-title":"BMC Cancer."},{"issue":"13","key":"1463_CR61","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/cncr.34223","volume":"128","author":"B De","year":"2022","unstructured":"De B, Tran Cao HS, Vauthey J, et al. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 2022;128(13):2529\u201339. https:\/\/doi.org\/10.1002\/cncr.34223.","journal-title":"Cancer."}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01463-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01463-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01463-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:15:13Z","timestamp":1781648113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01463-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01463-5","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}